Effects of vitamin D supplementation in type 1 diabetes mellitus patients

Conditions

Type 1 diabetes mellitus (DM1) Nutritional, Metabolic, Endocrine Type 1 diabetes mellitus (DM1)

João Soares Felício, Lorena Vilhena de Moraes, Gabriela Lemos, Ícaro José Araújo de Souza, Giovana Carvalho Vieira et al. (21 authors)

Scientific Reports2024-03-164 citations

10.1038/s41598-024-56934-1

de Souza ACCB, de Oliveira MCNI, de Lemos GN, da Silva ER, de Souza ÍJA, da Silva WM, de Alcântara AL, Said NM, de Moraes LV, Neto JFA, Dos Passos SR, Monteiro ÁAA, de Queiroz NNM, de Melo FTC, Felício KM, de Souza D'Albuquerque Silva L, Gomes DL, Mourão NAL, Piani PPF, Lobato IJC, Felício JS.

2022-03-282 citations

10.1186/s13098-022-00817-w

Improvement in Cardiovascular Autonomic Neuropathy After High-Dose Vitamin D Supplementation in Patients With Type 1 Diabetes

Lilian de Souza D’Albuquerque Silva, Natércia Neves Marques de Queiroz, Franciane Trindade Cunha de Melo, João Felício Abrahão Neto, Luísa Corrêa Janaú et al. (23 authors)

Frontiers in Endocrinology2020-11-1914 citations

10.3389/fendo.2020.605681

Interventions

All participants attend three scheduled study visits. At the first visit, participants undergo a physical examination, have blood samples taken and have a continuous glucose monitoring system (CGMS) f

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosis of type 1 diabetes mellitus 2. Aged between 18 and 50 years 3. Regular follow-up with an Endocrinologist 4. HbA1c =7% 5. Treatment with basal-bolus insulin (multiple daily injections) at a stable dose for at least 3 months prior visit 1 (variation of up to 10% of dose was permitted)

Exclusion criteria

Exclusion criteria: 1. Previous and concomitant history of metabolic bone diseases, liver disease, abnormal glomerular filtration rate (GFR) levels 2. Patients that made use of vitamin D or calcium within the last 3 months

Design outcomes

Primary

Measure	Time frame
Glycemic variability is assessed using continuous glucose monitoring from baseline to three months	—

Secondary

Measure	Time frame
1. Vitamin D (25(OH)D) levels are measured by immonoassay on blood samples collected at baseline and three months 2. Albuminuria levels are measured by immunoturbidimetry at baseline and three months 3. Autonomic cardiovascular neuropathy is measured by physical examination and ECG at baseline and three months	—

Countries

Brazil

Outcome results

None listed